SCHEMBL4293928

SCHEMBL4293928

CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc3c(c2)C(CCN(C)C)=C(C)C3)cc1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.69
ADRA2A P08913 2/20 0.58
HTR1A P08908 1/20 0.58
HTR2C P28335 1/20 0.55
HTT P42858 3/20 0.53
ALDH1A1 P00352 3/20 0.53
GAA P10253 1/20 0.53
PKM P14618 1/20 0.51
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14538994 0.89 HTT (0.56) HTR6HTTALDH1A1GAAPKM
SCHEMBL4292378 0.87 HTR6 (0.73) HTR6ADRA2AHTR1AHTR2CHTT
SCHEMBL2907974 0.83 HTR6 (0.57) HTR6HTTALDH1A1GAAPKM
SCHEMBL2906939 0.82 HTR6 (1.00) HTR6ADRA2AHTR1AHTR2CHTT
SCHEMBL2905695 0.75 HTR6 (1.00) HTR6ADRA2AHTR1AHTR2CHTT
SCHEMBL2902896 0.73 HTR6 (1.00) HTR6ADRA2AHTR1AHTR2CSMN1; SMN2
SCHEMBL4296156 0.72 HTR6 (0.67) HTR6ADRA2AHTR1AHTR2CHTT
SCHEMBL2900833 0.71 HTR6 (0.78) HTR6ADRA2AHTR1AHTR2CHTT
SCHEMBL2901197 0.71 HTR6 (1.00) HTR6ADRA2AHTR1AHTR2CHTT
SCHEMBL2905307 0.71 HTR6 (1.00) HTR6ADRA2AHTR1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217041-B2 Indene derivatives, their preparation and use as medicaments Laboratories del Sr. Esteve, S.A. (ES) 2012-07-10 US claimed
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US claimed
US-20090163547-A1 INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-06-25 US claimed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP claimed
US-8217041-B2 Indene derivatives, their preparation and use as medicaments Laboratories del Sr. Esteve, S.A. (ES) 2012-07-10 US disclosed
US-20090264457-A1 Combination of at least two 5HT6-Ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-10-22 US disclosed
US-20090163547-A1 INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-06-25 US disclosed
EP-2020230-A1 Combination of at least two 5-HT6-Ligands Laboratorios del Dr. Esteve S.A. (ES) 2009-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264457-A1 Combination of at least two 5HT6-Ligands HTR6, HTR3B, HTR4 HTR6 1/4885ADRA2A 65/4885HTR1A 8/4885
US-20090163547-A1 INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS HTR6, HTR5A, HTR1A HTR6 1/4885ADRA2A 25/4885HTR1A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.